Heart failure & cardiomyopathies
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF
Authors' conclusion
Black patients treated with omecamtiv mecarbil had similar benefit and safety compared with White counterparts.
Study context
- Population
- Symptomatic heart failure (HF), elevated natriuretic peptides, left ventricular ejection fraction (LVEF) ≤35%; Black vs White patients in countries contributing ≥10 Black participants
- Participants
- 562 Black patients
- Comparison
- Omecamtiv mecarbil vs placebo in Black vs White patients
- Primary endpoint
- Composite of:
- Time to first HF event
- CV death
Methodological detailssubgroup analysis by race
- Subgroup analysis by race
Primary result
As reported in the abstract
Primary endpoint, Black vs White patients
Hazard ratio
0.83
Black patients
Hazard ratio
0.88
White patients
Further findings
Heart rate and NT-proBNP
- Similar improvements in Black vs White patients
Placebo-corrected change in BP from baseline, Black vs White patients
mm Hg
- Black patients
- +3.4
- White patients
- −0.7
- P for interaction = 0.02
- Only nominally significant treatment-by-race interaction
Original publication
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF. JACC Heart Fail. Published 1 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →